Two Current Topics in Coagulation and Fibrinolysis

[1]  W. Schneider.  [Tumor, thrombocytosis and thrombosis risk]. , 2008, Deutsche medizinische Wochenschrift.

[2]  Y. Sakata,et al.  The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia , 1991 .

[3]  M. Kramer,et al.  Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. , 1991, Experimental cell research.

[4]  M. Baker,et al.  Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. , 1990, Cancer research.

[5]  Bonnie F. Sloane,et al.  Role for cathepsin B and cystatins in tumor growth and progression. , 1990, Biological chemistry Hoppe-Seyler.

[6]  K. Ulm,et al.  Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .

[7]  T. Issekutz.  Effects of six different cytokines on lymphocyte adherence to microvascular endothelium and in vivo lymphocyte migration in the rat. , 1990, Journal of immunology.

[8]  M. Wojtukiewicz,et al.  Clotting factors in tumour tissue: implications for cancer therapy. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[9]  A. Shibata,et al.  Thrombin Vs. Plasmin generation in disseminated lntravascular coagulation associated with various underlying disorders , 1990, American journal of hematology.

[10]  B. Thomson,et al.  Type I collagen degradation by mouse calvarial osteoblasts stimulated with 1,25-dihydroxyvitamin D-3: evidence for a plasminogen-plasmin-metalloproteinase activation cascade. , 1989, Biochimica et biophysica acta.

[11]  H. Remold,et al.  Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. , 1989, Journal of immunology.

[12]  H. Vinazzer.  Therapeutic Use of Antithrombin III in Shock and Disseminated Intravascular Coagulation , 1989, Seminars in thrombosis and hemostasis.

[13]  A. Eisen,et al.  Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Baker.  Clinical Aspects of Disseminated Intravascular Coagulation: A Clinician's Point of View , 1989, Seminars in thrombosis and hemostasis.

[15]  G. Müller‐Berghaus.  Pathophysiologic and Biochemical Events in Disseminated Intravascular Coagulation: Dysregulation of Procoagulant and Anticoagulant Pathways , 1989, Seminars in thrombosis and hemostasis.

[16]  R. Jordan,et al.  Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. , 1988, Circulatory shock.

[17]  D. Feinstein.  Treatment of Disseminated Intravascular Coagulation , 1988, Seminars in thrombosis and hemostasis.

[18]  J. Lisiewicz.  Disseminated Intravascular Coagulation in Acute Leukemia , 1988, Seminars in thrombosis and hemostasis.

[19]  S. Karpatkin,et al.  Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. , 1988, The Journal of clinical investigation.

[20]  F. Cozzolino,et al.  Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. , 1988, The American journal of medicine.

[21]  P. D’Amore,et al.  Antiangiogenesis as a Strategy for Antimetastasis , 1988, Seminars in thrombosis and hemostasis.

[22]  J. Talmadge,et al.  Immunotherapy of Metastatic Disease , 1988, Seminars in thrombosis and hemostasis.

[23]  F. Orr,et al.  Interactions of cancer cells with the microvasculature during metastasis 1 2 , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  E. Bastida.  The Metastatic Cascade: Potential Approaches for the Inhibition of Metastasis , 1988, Seminars in thrombosis and hemostasis.

[25]  W. Hancock,et al.  Antimetastatic Agents. I. Role of Cellular Procoagulants in the Pathogenesis of Fibrin Deposition in Cancer and the Use of Anticoagulants and/or Antiplatelet Drugs in Cancer Treatment , 1988, Seminars in thrombosis and hemostasis.

[26]  F. Rickles,et al.  Antimetastatic Agents. II. Summary of the Interactions of Tumor Cells with Blood Coagulation Factors, Platelets, Fibrinolytic Factors, and Inflammatory Cells and Their Soluble Mediators: Potential for Therapeutic Interventions , 1988, Seminars in thrombosis and hemostasis.

[27]  J. Cajot,et al.  Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines , 1986, International journal of cancer.

[28]  Y. Sasaki,et al.  The significance of the fibrin/fibrinogen degradation product in serum of carcinoma patients with hematogenous metastasis , 1986, Cancer.

[29]  E. Mammen,et al.  Human Antithrombin Concentrates and Experimental Disseminated Intravascular Coagulation , 1985, Seminars in thrombosis and hemostasis.

[30]  P. Ostendorf,et al.  Disseminierte intravasale Gerinnung (DIC) und Verbrauchskoagulopathie: Sepsis und Schock , 1985 .

[31]  L. Liotta,et al.  Laminin molecular domains which alter metastasis in a murine model. , 1984, The Journal of clinical investigation.

[32]  D. Triantaphyllopoulos.  Effects of Human Antithrombin III on Mortality and Blood Coagulation Induced in Rabbits by Endotoxin , 1984, Thrombosis and Haemostasis.

[33]  G. Markus.  The Role of Hemostasis and Fibrinolysis in the Metastatic Spread of Cancer , 1984, Seminars in thrombosis and hemostasis.

[34]  P. Ockelford,et al.  Disseminated Intravascular Coagulation: The Application and Utility of Diagnostic Tests , 1982, Seminars in thrombosis and hemostasis.

[35]  M. Modan,et al.  Clinical and Laboratory Aspects of Disseminated Intravascular Coagulation (DIC): A Study of 118 Cases , 1978, Thrombosis and Haemostasis.

[36]  L. Harker,et al.  HEMOSTASIS IN MALIGNANCY * † , 1974, Annals of the New York Academy of Sciences.

[37]  L. T. Mann,et al.  Antithrombin III: Protection against Death after Injection of Thromboplastin , 1969, Science.

[38]  T. Abe,et al.  [Fibrinolysis in cancer]. , 1969, Gan no rinsho. Japan journal of cancer clinics.

[39]  C. Stewart,et al.  Antimetastatic effects associated with platelet reduction. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Morrison.  An analysis of the blood picture in 100 cases of malignancy , 1932 .

[41]  L. Ossowski,et al.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. , 1991, Cancer research.

[42]  G. Lowe,et al.  Coagulation disturbances in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products. , 1990, Haemostasis.

[43]  N. Heimburger,et al.  Hämostase, Fibrinolyse, Proteolyse : Wechsselwirkungen mit Entzündungsreaktionen , 1990 .

[44]  M. Jochum,et al.  Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs. , 1990, The American review of respiratory disease.

[45]  F. Seiler,et al.  Struktur und Biologie von Interleukinen: Der Einfluß von IL-1 und TNFα auf Endothelzellen und das Gerinnungssystem , 1990 .

[46]  A. Lindahl,et al.  Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. , 1990, Haemostasis.

[47]  W. Schneider.  Bedeutung von Hämostasestörungen für Diagnostik und Therapie von Tumorkrankheiten , 1988 .

[48]  Bonnie F. Sloane,et al.  Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. , 1988, Haemostasis.

[49]  D. Rifkin,et al.  New aspects of blood vessel growth: tumor and tissue-derived angiogenesis factors. , 1988, Haemostasis.

[50]  N. Semeraro.  Different expression of procoagulant activity in macrophages associated with experimental and human tumors. , 1988, Haemostasis.

[51]  A. Ordinas,et al.  Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. , 1988, Haemostasis.

[52]  M. Donati,et al.  Expression of plasminogen activator as a marker of stimulation in tumor-associated macrophages. , 1988, Haemostasis.

[53]  F. Rickles,et al.  Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients. , 1988, Haemostasis.

[54]  T. Emerson,et al.  Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat. , 1987, Circulatory shock.

[55]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[56]  N. Semeraro,et al.  Cancer cell procoagulants and their pharmacological modulation. , 1984, Haemostasis.

[57]  T. Yoshikawa,et al.  Protective effect of gabexate mesilate against experimental disseminated intravascular coagulation in rats. , 1983, Haemostasis.

[58]  T. Yoshikawa,et al.  Effects of FUT-175, a New Synthetic Protease Inhibitor on Endotoxin-Induced Disseminated Intravascular Coagulation in Rats , 1983 .

[59]  G. Müller‐Berghaus,et al.  Microcirculatory Disturbances Induced by Generalized Intravascular Coagulation , 1975 .